Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cell Design Labs

- PMLiVE

Gilead wins European approval for triple hep C combination Vosevi

The treatment brings together sofosbuvir, velpatasvir and voxilaprevir

- PMLiVE

Kite wins FDA approval for blood cancer drug Yescarta

Becomes the first CAR-T therapy approved in the US for B-cell lymphoma

Gilead Sciences promotes Dr Alessandro Riva to EVP, oncology therapeutics

He's been with the firm since January, when he joined from Novartis

- PMLiVE

Cellectis floored by patient death in CAR-T trial

FDA puts two cancer immunotherapy trials on hold

Roche Basel Switzerland

Roche claims its own CAR-T first with orphan drug Actemra

Comes as FDA approves the first CAR-T therapy from Novartis

- PMLiVE

Novartis claims first CAR-T approval, setting $475k price tag

Kymriah receives FDA nod to treat ALL patients

- PMLiVE

Gilead makes $11.9bn play for CAR-T specialist Kite

The agreement is due to close in this year’s fourth quarter

- PMLiVE

Intriguing data with Juno’s new CAR-T therapy

Suggests a long treatment effect from the biotech's JCAR017 candidate

- PMLiVE

Kite starts EU trial of lead CAR-T therapy

Adult patients with DLBCL, PMBCL and TFL will be enrolled in the trial

- PMLiVE

Kite files first CAR-T candidate in Europe

But will need to play catch up in the US, where Novartis has a slight lead

- PMLiVE

Novartis’ CAR-T clears FDA panel with relative ease

Puts tisagenlecleucel-T on course to be first approved personalised CAR-T therapy

Novartis day

Novartis files CAR-T therapy in US, with swift review

CTL109 candidate gets FDA priority review status

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links